Serelaxin a novel treatment for acute heart failure

References

• Fonarow GC, Abraham WT, Albert NM, et al. Influence of a performance-improvement initiative on quality of care for patients hospitalized with heart failure: results of the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF). Arch Intern Med 2007;167(14):1493-502
   PubMed Web of Science ®Google Scholar
• Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics–2014 update: a report from the American Heart Association. Circulation 2014;129(3):e28-e292
   PubMed Web of Science ®Google Scholar
• Stevenson LW. Are hemodynamic goals viable in tailoring heart failure therapy? Hemodynamic goals are relevant. Circulation 2006;113(7):1020-7. discussion 33
   PubMed Web of Science ®Google Scholar
• Cotter G, Metra M, Milo-Cotter O, et al. Fluid overload in acute heart failure–re-distribution and other mechanisms beyond fluid accumulation. Eur J Heart Fail 2008;10(2):165-9
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Follath F, Ponikowski P, et al. Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. Eur J Heart Fail 2010;12(5):423-33
   PubMed Web of Science ®Google Scholar
• Teerlink JR, Cotter G, Davison BA, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 2013;381(9860):29-39
   PubMed Web of Science ®Google Scholar
• Metra M, Cotter G, Davison BA, et al. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol 2013;61(2):196-206
   PubMed Web of Science ®Google Scholar
• Stewart DR, Celniker AC, Taylor CAJr, et al. Relaxin in the peri-implantation period. J Clin Endocrinol Metab 1990;70(6):1771-3
   PubMed Web of Science ®Google Scholar
• Dschietzig T, Richter C, Bartsch C, et al. The pregnancy hormone relaxin is a player in human heart failure. FASEB J 2001;15(12):2187-95
   PubMed Web of Science ®Google Scholar
• Gavino ES, Furst DE. Recombinant relaxin: a review of pharmacology and potential therapeutic use. BioDrugs 2001;15(9):609-14
   PubMed Web of Science ®Google Scholar
• Available from: www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM390444.pdf
   Google Scholar
• Kobalava Z, Villevalde S, Kotovskaya Y, et al. Pharmacokinetics of serelaxin in patients with hepatic impairment: A single-dose, open-label, parallel-group study. Br J Clin Pharmacol 2014. [Epub ahead of print]
   Google Scholar
• International 4700 en venta. Available from: www.marketbook.gt/list/list.aspx?OHID=4393905&Manu=INTERNATIONAL&ETID=1&Mdltxt=4700&MdlX=Contains&notfound=1&LP=TRK
   Google Scholar
• Kumagai J, Hsu SY, Matsumi H, et al. INSL3/Leydig insulin-like peptide activates the LGR8 receptor important in testis descent. J Biol Chem 2002;277(35):31283-6
   PubMed Web of Science ®Google Scholar
• Bathgate RA, Halls ML, van der Westhuizen ET, et al. Relaxin family peptides and their receptors. Physiol Rev 2013;93(1):405-80
   PubMed Web of Science ®Google Scholar
• Novak J, Parry LJ, Matthews JE, et al. Evidence for local relaxin ligand-receptor expression and function in arteries. FASEB J 2006;20(13):2352-62
   PubMed Web of Science ®Google Scholar
• Haynes WG, Webb DJ. Endothelin as a regulator of cardiovascular function in health and disease. J Hypertens 1998;16(8):1081-98
   PubMed Web of Science ®Google Scholar
• Schneider MP, Boesen EI, Pollock DM. Contrasting actions of endothelin ET(A) and ET(B) receptors in cardiovascular disease. Annu Rev Pharmacol Toxicol 2007;47:731-59
   PubMed Web of Science ®Google Scholar
• Chow BS, Chew EG, Zhao C, et al. Relaxin signals through a RXFP1-pERK-nNOS-NO-cGMP-dependent pathway to up-regulate matrix metalloproteinases: the additional involvement of iNOS. PLoS One 2012;7(8):e42714
   PubMed Web of Science ®Google Scholar
• Sasser JM, Molnar M, Baylis C. Relaxin ameliorates hypertension and increases nitric oxide metabolite excretion in angiotensin II but not N(omega)-nitro-L-arginine methyl ester hypertensive rats. Hypertension 2011;58(2):197-204
   PubMed Web of Science ®Google Scholar
• Masini E, Nistri S, Vannacci A, et al. Relaxin inhibits the activation of human neutrophils: involvement of the nitric oxide pathway. Endocrinology 2004;145(3):1106-12
   PubMed Web of Science ®Google Scholar
• Fisher C, MacLean M, Morecroft I, et al. Is the pregnancy hormone relaxin also a vasodilator peptide secreted by the heart? Circulation 2002;106(3):292-5
   PubMed Web of Science ®Google Scholar
• Dschietzig T, Bartsch C, Richter C, et al. Relaxin, a pregnancy hormone, is a functional endothelin-1 antagonist: attenuation of endothelin-1-mediated vasoconstriction by stimulation of endothelin type-B receptor expression via ERK-1/2 and nuclear factor-kappaB. Circ Res 2003;92(1):32-40
   PubMed Web of Science ®Google Scholar
• Conrad KP, Shroff SG. Effects of relaxin on arterial dilation, remodeling, and mechanical properties. Curr Hypertens Rep 2011;13(6):409-20
   PubMed Web of Science ®Google Scholar
• Jelinic M, Leo CH, Post Uiterweer ED, et al. Localization of relaxin receptors in arteries and veins, and region-specific increases in compliance and bradykinin-mediated relaxation after in vivo serelaxin treatment. FASEB J 2014;28(1):275-87
   PubMed Web of Science ®Google Scholar
• Conrad KP. Maternal vasodilation in pregnancy: the emerging role of relaxin. Am J Physiol Regul Integr Comp Physiol 2011;301(2):R267-75
   PubMed Web of Science ®Google Scholar
• Teichman SL, Unemori E, Teerlink JR, et al. Relaxin: review of biology and potential role in treating heart failure. Curr Heart Fail Rep 2010;7(2):75-82
   PubMedGoogle Scholar
• Smith MC, Danielson LA, Conrad KP, et al. Influence of recombinant human relaxin on renal hemodynamics in healthy volunteers. J Am Soc Nephrol 2006;17(11):3192-7
   PubMed Web of Science ®Google Scholar
• Samuel CS, Unemori EN, Mookerjee I, et al. Relaxin modulates cardiac fibroblast proliferation, differentiation, and collagen production and reverses cardiac fibrosis in vivo. Endocrinology 2004;145(9):4125-33
   PubMed Web of Science ®Google Scholar
• Heeg MH, Koziolek MJ, Vasko R, et al. The antifibrotic effects of relaxin in human renal fibroblasts are mediated in part by inhibition of the Smad2 pathway. Kidney Int 2005;68(1):96-109
   PubMed Web of Science ®Google Scholar
• Mookerjee I, Hewitson TD, Halls ML, et al. Relaxin inhibits renal myofibroblast differentiation via RXFP1, the nitric oxide pathway, and Smad2. FASEB J 2009;23(4):1219-29
   PubMed Web of Science ®Google Scholar
• Dschietzig T, Teichman S, Unemori E, et al. Intravenous recombinant human relaxin in compensated heart failure: a safety, tolerability, and pharmacodynamic trial. J Card Fail 2009;15(3):182-90
   PubMed Web of Science ®Google Scholar
• Teerlink JR, Metra M, Felker GM, et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet 2009;373(9673):1429-39
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Mitrovic V, Ruda M, et al. A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure. Eur Heart J 2014;35(7):431-41
   PubMed Web of Science ®Google Scholar
• Voors AA, Dahlke M, Meyer S, et al. Renal hemodynamic effects of serelaxin in patients with chronic heart failure: a randomized, placebo-controlled study. Circ Heart Fail 2014;7(6):994-1002
   PubMed Web of Science ®Google Scholar
• Anderson S, Brenner BM. The role of intraglomerular pressure in the initiation and progression of renal disease. J Hypertens Suppl 1986;4(5):S236-8
   PubMedGoogle Scholar
• Metra M, Ponikowski P, Cotter G, et al. Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF. Eur Heart J 2013;34(40):3128-36
   PubMed Web of Science ®Google Scholar
• Filippatos G, Teerlink JR, Farmakis D, et al. Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial. Eur Heart J 2013; Epub ahead of print
   Google Scholar
• Mehra S, Walker J, Patterson K, et al. Autoantibodies in systemic sclerosis. Autoimmun Rev 2013;12(3):340-54
   PubMed Web of Science ®Google Scholar
• Safety of repeat doses of IV serelaxin in subjects with chronic heart failure (RELAX-REPEAT). Available from: https://clinicaltrials.gov/ct2/show/NCT01982292
   Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;62(16):e147-239
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012;14(8):803-69
   PubMed Web of Science ®Google Scholar
• Valente MA, Voors AA, Damman K, et al. Diuretic response in acute heart failure: clinical characteristics and prognostic significance. Eur Heart J 2014; Epub ahead of print
   Google Scholar
• Leto L, Aspromonte N, Feola M. Efficacy and safety of loop diuretic therapy in acute decompensated heart failure: a clinical review. Heart Fail Rev 2014;19(2):237-46
   PubMed Web of Science ®Google Scholar
• Metra M, Cotter G, Gheorghiade M, et al. The role of the kidney in heart failure. Eur Heart J 2012;33(17):2135-42
   PubMed Web of Science ®Google Scholar
• Wakai A, McCabe A, Kidney R, et al. Nitrates for acute heart failure syndromes. Cochrane Database Syst Rev 2013;8:CD005151
   PubMedGoogle Scholar
• Metra M, Bettari L, Carubelli V, et al. Use of inotropic agents in patients with advanced heart failure: lessons from recent trials and hopes for new agents. Drugs 2011;71(5):515-25
   PubMed Web of Science ®Google Scholar
• O’Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011;365(1):32-43
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Teerlink JR, Cotter G, et al. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA 2007;298(17):2009-19
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Konstam MA, Burnett JC, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 2007;297(12):1332-43
   PubMed Web of Science ®Google Scholar
• Massie BM, O’Connor CM, Metra M, et al. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med 2010;363(15):1419-28
   PubMed Web of Science ®Google Scholar
• Pang PS, Konstam MA, Krasa HB, et al. Effects of tolvaptan on dyspnoea relief from the EVEREST trials. Eur Heart J 2009;30(18):2233-40
   PubMed Web of Science ®Google Scholar
• Metra M, Bugatti S, Bettari L, et al. Can we improve the treatment of congestion in heart failure? Expert Opin Pharmacother 2011;12(9):1369-79
   PubMed Web of Science ®Google Scholar
• Rehman SU, Mueller T, Januzzi JLJr. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J Am Coll Cardiol 2008;52(18):1458-65
   PubMed Web of Science ®Google Scholar
• Rogowski O, Shnizer S, Wolff R, et al. Increased serum levels of oxidative stress are associated with hospital readmissions due to acute heart failure. Cardiology 2011;118(1):33-7
   PubMed Web of Science ®Google Scholar
• Kalogeropoulos AP, Tang WH, Hsu A, et al. High sensitivity C-reactive protein in acute heart failure: Insights from the ASCEND-HF trial. J Card Fail 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Shantsila E, Wrigley BJ, Blann AD, et al. A contemporary view on endothelial function in heart failure. Eur J Heart Fail 2012;14(8):873-81
   PubMed Web of Science ®Google Scholar
• Fischer D, Rossa S, Landmesser U, et al. Endothelial dysfunction in patients with chronic heart failure is independently associated with increased incidence of hospitalization, cardiac transplantation, or death. Eur Heart J 2005;26(1):65-9
   PubMed Web of Science ®Google Scholar
• Katz SD, Hryniewicz K, Hriljac I, et al. Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure. Circulation 2005;111(3):310-14
   PubMed Web of Science ®Google Scholar
• Meyer B, Mortl D, Strecker K, et al. Flow-mediated vasodilation predicts outcome in patients with chronic heart failure: comparison with B-type natriuretic peptide. J Am Coll Cardiol 2005;46(6):1011-18
   PubMed Web of Science ®Google Scholar
• Baccari MC, Bani D. Relaxin and nitric oxide signalling. Current protein & peptide science 2008;9(6):638-45
   PubMed Web of Science ®Google Scholar
• Kociol RD, Pang PS, Gheorghiade M, et al. Troponin elevation in heart failure prevalence, mechanisms, and clinical implications. J Am Coll Cardiol 2010;56(14):1071-8
   PubMed Web of Science ®Google Scholar
• Ronco C, Cicoira M, McCullough PA. Cardiorenal syndrome type 1: pathophysiological crosstalk leading to combined heart and kidney dysfunction in the setting of acutely decompensated heart failure. J Am Coll Cardiol 2012;60(12):1031-42
   PubMedGoogle Scholar
• Nikolaou M, Parissis J, Yilmaz MB, et al. Liver function abnormalities, clinical profile, and outcome in acute decompensated heart failure. Eur Heart J 2013;34(10):742-9
   PubMed Web of Science ®Google Scholar